Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: J Neurol Neurosurg Psychiatry. 2015 Jan 24;86(12):1324–1330. doi: 10.1136/jnnp-2014-309421

Table 1.

Clinical factors for the patients based on clinical consensus diagnoses separated into the four major diagnostic categories

Factors LA
n=13
MI
n=9
MX
n=5
BD
n=25
p Value*
Age        67 (15)        54 (13)        78 (7)        66 (9)   0.004
Hypertension          4 (31%)          7 (78%)          4 (80%)        13 (52%)   0.099
Diabetes mellitus          1 (8%)          3 (33%)          2 (40%)          6 (24%)   0.379
Hyper-reflexia          6 (46%)          9 (100%)          4 (80%)        17 (68%)   0.057
Imbalance          5 (38%)          6 (67%)          4 (80%)        20 (80%)   0.068
Executive   46.23 (7.17)   45.62 (10.53)   42.20 (3.96)   40.96 (7.60)   0.207
N-acetylaspartate   12.64 (1.08)   12.25 (1.48)   10.74 (1.09)   10.31 (1.58) <0.001
Albumin index     4.29 (1.76)     7.43 (1.90)     6.55 (4.56)     7.71 (2.15)   0.010
BBB permeability Ki 0.0019 (0.0011) 0.0017 (0.0007) 0.0016 (0.0009) 0.0034 (0.0051)   0.501
MMP-2 CSF     3.37 (3.02)     3.73 (2.95)     5.15 (7.21)     3.31 (3.83)   0.833
MMP-2 blood   54.89 (31.16)   57.30 (27.79)   50.20 (34.07)   54.24 (32.78)   0.985
Aβ42      220 (107)      329 (65)      115 (44)      228 (113)   0.009
P-τ181   33.43 (19.54)   32.29 (11.94)   51.00 (65.2)   31.33 (12.58)   0.486
*

p Values from χ2 values for categorical variables, ANOVA for continuous variables.

Means (SD).

Count (percentage within category).

Aβ42, amyloid-β1–42; ANOVA, analysis of variance; BBB, blood-brain barrier; BD, Binswanger disease; CSF, cerebrospinal fluid; LA, leucoaraiosis; MI, multiple infarcts; MMP, matrix metalloproteinases; MX, mixed dementia; P-τ181, phosphorylated-τ181.